Patents by Inventor Fabao LIU

Fabao LIU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic cationic peptides and unimolecular nanoparticles for efficient delivery thereof
    Patent number: 11672766
    Abstract: Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be used in the treatment of breast cancer and other diseases or conditions in which PKM2 is overexpressed. Such PKM2 peptides may be delivered to cancer cells using pH sensitive unimolecular nanoparticles comprising anionic polymers.
    Type: Grant
    Filed: April 10, 2020
    Date of Patent: June 13, 2023
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Shaoqin Gong, Wei Xu, Yuyuan Wang, Fabao Liu
  • THERAPEUTIC CATIONIC PEPTIDES AND UNIMOLECULAR NANOPARTICLES FOR EFFICIENT DELIVERY THEREOF
    Publication number: 20200276130
    Abstract: Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be used in the treatment of breast cancer and other diseases or conditions in which PKM2 is overexpressed. Such PKM2 peptides may be delivered to cancer cells using pH sensitive unimolecular nanoparticles comprising anionic polymers.
    Type: Application
    Filed: April 10, 2020
    Publication date: September 3, 2020
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Shaoqin GONG, Wei XU, Yuyuan WANG, Fabao LIU
  • Therapeutic cationic peptides and unimolecular nanoparticles for efficient delivery thereof
    Patent number: 10660860
    Abstract: Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be used in the treatment of breast cancer and other diseases or conditions in which PKM2 is overexpressed. Such PKM2 peptides may be delivered to cancer cells using pH sensitive unimolecular nanoparticles comprising anionic polymers.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: May 26, 2020
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Shaoqin Gong, Wei Xu, Yuyuan Wang, Fabao Liu
  • UNIMOLECULAR NANOPARTICLES FOR EFFICIENT DELIVERY OF THERAPEUTIC CATIONIC PEPTIDES
    Publication number: 20180235897
    Abstract: Provided herein are peptides comprising an amino acid sequence having at least about 85% sequence identity to RYRPRAPIIAVT (SEQ ID NO: 1). These cationic peptides inhibit PKM2 methylation and may be used in the treatment of breast cancer and other diseases or conditions in which PKM2 is overexpressed. Such PKM2 peptides may be delivered to cancer cells using pH sensitive unimolecular nanoparticles comprising anionic polymers.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 23, 2018
    Applicant: Wisconsin Alumni Research Foundation
    Inventors: Shaoqin GONG, Wei XU, Yuyuan WANG, Fabao LIU